---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-273985"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:14:29.483411+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TScan reports positive Phase 1 ALLOHA data; plans registrational trial for TSC-101 in H2 2025

## Summary
- Event-free survival strongly favored treatment arm (HR=0.30, p=0.04); relapse probability trended lower (HR=0.28, p=0.14).
- 2 of 26 (8%) treatment-arm patients relapsed vs 4 of 12 (33%) controls; median time to relapse not evaluable vs 160 days.
- No TP53-mutated patients relapsed in treatment arm (0/4 infused), while both control-arm TP53 patients relapsed within 6 months and died.
- Registrational trial for TSC-101 planned for H2 2025 with RFS primary endpoint, powered at HR 0.60, 85% power, ~140 treatment subjects.
- Solid tumor program: 8 patients infused singleplex; first T-Plex product manufactured; IND for MAGE-A4 TCR submitted.

## SEC filing metadata
- accession: 0001193125-24-273985
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312524273985/0001193125-24-273985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312524273985/d917413d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-273985
- JSON: https://secwatch.observer/filing/0001193125-24-273985.json
- Plain text: https://secwatch.observer/filing/0001193125-24-273985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.